Adimmune Corporation (TPE:4142)
Taiwan · Delayed Price · Currency is TWD 18.50
-0.20 (-1.07%)
Apr 17, 2026, 1:30 PM CST
Adimmune Revenue
In the year 2025, Adimmune had annual revenue of 1.40B TWD, down -9.99%. Adimmune had revenue of 745.46M in the quarter ending December 31, 2025, with 36.76% growth.
Revenue
1.40B
Revenue Growth
-9.99%
P/S Ratio
5.56
Revenue / Employee
2.48M
Employees
564
Market Cap
7.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | -155.49M | -9.99% |
| Dec 31, 2024 | 1.56B | -228.11M | -12.78% |
| Dec 31, 2023 | 1.79B | -466.53M | -20.72% |
| Dec 31, 2022 | 2.25B | 457.85M | 25.52% |
| Dec 31, 2021 | 1.79B | -75.37M | -4.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.37B |
| Savior Lifetec | 1.20B |
| PharmaEngine | 911.42M |
| Mycenax Biotech | 740.24M |
| Tanvex BioPharma | 400.97M |
| TaiGen Biopharmaceuticals Holdings | 259.47M |
| Gongwin Biopharm Holdings | 36.45M |
| Locus Cell | 12.74M |